| Synonyms |
(S)-N1-((1H-benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; AMD11070; AMD-11070; AMD 11070; AMD-070; AMD 070; AMD070 |
| IUPAC Name |
N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine |
| Molecular Weight |
349.47 |
| Molecular Formula |
C21H27N5 |
| Canonical SMILES |
NCCCCN(CC1=NC2=CC=CC=C2N1)[C@H]3CCCC4=C3N=CC=C4 |
| InChI |
1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1 |
| InChIKey |
WVLHHLRVNDMIAR-IBGZPJMESA-N |
| Melting Point |
108-110 °C |
| Purity |
≥98% (HPLC) |
| Solubility |
10 mM in DMSO |
| Appearance |
White to gray solid |
| Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| Complexity |
431 |
| Exact Mass |
349.22664588 |
| In Vitro |
Mavorixafor (AMD-070) is a potent and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively. Mavorixafor (AMD-070) shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2). Mavorixafor (AMD-070) (6.6 µM) significantly suppresses the anchorage-dependent growth, the migration and matrigel invasion of the B88-SDF-1 cells. |
| In Vivo |
Mavorixafor (AMD-070) (2 mg/kg, p.o.) significantly reduces the number of metastatic lung nodules in mice, and lowers the expression of human Alu DNA in mice, without body weight loss. |
| Target |
CXCR; HIV |
| XLogP3-AA |
2.4 |
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/558447-26-0.gif)
